Inhibiting HIF1α in combination with anti-angiogenic therapy reduces CSCs in mouse models of breast cancer and holds promise to be an effective therapy in breast cancer, which is currently being investigated in clinical trials [64]. Here, HIF1A is linked to breast cancer.